Active	Status	Sponsor type	Region	Phase	Filter
3 Active 4 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BNT321 / BioNTech
NCT06069778: Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma	Recruiting	1/2	320	US	BNT321 Dose Level 1, BNT321 Dose Level 2, mFOLFIRINOX, BNT321 RP2D	BioNTech SE	Pancreatic Cancer	04/29	06/31
MV-0715-CP-001.01, NCT02672917: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies	Active, not recruiting	1	118	US	MVT-5873, HuMab-5B1, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel	BioNTech Research & Development, Inc.	Pancreatic Cancer	08/24	10/26
NCT04883775: Study of a New Technique for Imaging Pancreatic Cancer	Active, not recruiting	1	4	US	MVT-2163, 89Zr-DFO-HuMab-5B1, MVT-5873	Memorial Sloan Kettering Cancer Center, BioNTech SE	Pancreatic Cancer, Tumors That Express CA19-9	05/25	05/25
MVT-1075 / BioNTech
No trials found
177Lu-TE-1132 / T-E Pharma
No trials found